Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma
after autologous transplantation. Non-myeloablative allogeneic transplantation allows
patients to receive an infusion of donor cells in an attempt to induce a graft versus
lymphoma effect. This study will assess the feasibility, safety and efficacy of the
combination of autologous stem cell transplantation followed by non-myeloablative
transplantation for patients with poor-risk aggressive lymphoma.